Drug Development

Biomedcode has been and is a partner of choice in European and National Research Networks that aim at the study of disease mechanisms and the discovery of novel therapeutics focusing on topics such as Rheumatoid Arthritis, Inflammation, Cancer, Aging etc.

Developed Drugs

2021- 2024

BioOnChip

A nationally funded collaborative research project aiming at interrogating the applicability of an innovative 3D microfluidic microculture, i.e. tumor-on-chip, in predicting real-time responses to PD1-blockade in NSCLC patients.

2020-2023

sepia

A nationally funded collaborative research project aiming at the development of an optimized preclinical spondyloarthritis platform with integrated high end imaging technology readouts offering capabilities for the continuous monitoring of disease progression as well as its response to treatment.

2020-2023

DrugArt

A nationally funded collaborative research project aiming at the synthesis of novel small molecules against chronic inflammatory diseases, using lead compounds already validated by the team’s researchers.

2018-2021

BreastCaRANKL

A nationally funded collaborative research project aiming at the development of an innovative human-RANKL dependent breast cancer mouse model towards the development of novel preclinical platforms for the evaluation of human therapeutics targeting cancer.

2018-2021

HUPLA

A nationally funded collaborative research project aiming at the development of humanized platforms that will allow the evaluation of therapeutics targeting autoimmune pathologies

2017-2020

INFRAFRONTIER

A funding scheme supporting the development of a world-class research infrastructure that will provide enduring mouse resources and services towards advancing research into human health and disease.

2011-2015

Be The Cure

An IMI (Innovative Medicines Initiative) funded research project aiming to develop new therapies against rheumatoid arthritis.

2012-2016

aDDRess

An FP7 Marie Curie ITN focusing on the study of chromatin dynamics and the DNA damage response also in pathologies such as intestinal inflammation and cancer.

2012-2016

CodeAge

An FP7 Marie Curie ITN focusing on the role of chronic DNA damage in ageing and age-related pathology including arthritis.

2011-2014

TheRAlead

A National Network of Excellence collaborative project aiming to establish a drug pipeline towards the development of novel therapeutic lead compounds targeting arthritis

2012-2015

TARKINAID

A collaborative research project aiming at targeting Src-family kinases for the treatment of chronic autoimmune and inflammatory disorders including arthritis.

2008-2013

masterswitch project

A large scale integrating project focusing on the study of disease mechanisms with the aim to attack steering effectors of Rheumatoid Syndromes with innovative therapy choices.

2009-2012

infla-Care

A large scale integrating project focusing on the understanding of inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies.

2005-2019

MUGEN

FP6 Network of Excellence aiming towards integrated Functional Genomics in Mutant Mouse Models as Tools to Investigate the Complexity of Human Immunological Disease.

Medicinal Chemistry

Ex vivo validation

Precision Cut Lung Slices

In Vivo Validation

PK/PD studies

Mouse models of Inflammation

Mouse models of fibrosis

New Anti-inflammatory Pharmacophore

In Vitro Validation

Inflammatory activation Fibrosis Assays

ADMET Studies

Development Cycle

Tap to zoom in

R&D

Mouse Model Development

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

;

Assay Development

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

;

Research Projects

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.

Publications

Et harum quidem rerum facilis est et expedita mea voluptas fuga quod mea.